Xcout IntelSerenatis Bio competitors & alternatives
The 12 closest competitors and alternatives to Serenatis Bio among biotechnology companies — ranked by similarity to what Serenatis Bio actually does, not by market-cap band.
Subscribe to see Serenatis Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Serenatis Bio
Serenatis Bio is a biotechnology company founded in 2024 and headquartered in Cambridge, United Kingdom. It is developing novel, precision therapeutics for obsessive-compulsive disorder (OCD).
Serenatis Bio at a glance
Serenatis Bio is a biotechnology company headquartered in United Kingdom. Its most recent funding round, Pre-Seed, closed in June 2025. Xcout tracks 5 named people at Serenatis Bio, including Julia Jones (CFO).
Serenatis Bio leadership
- Julia JonesCFO
- David CavallaCEO & Co-founder
- Nick SireauExecutive Chairman & Co-founder
- Natalie PankovaBoard Director
- Susanne StuffersBoard Director
Serenatis Bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Pre-Seed | Undisclosed | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Serenatis Bio competitors
Ranked by semantic similarity — how close each company is to Serenatis Bio by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Solvonis Therapeutics plc is a biopharmaceutical company that develops novel medicines for central nervous system (CNS) disorders. Its initial therapeutic focus is on treating Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), with discovery programs extending into broader addiction, psychiatry, and neurology fields.
Life Sciences (Therapeutics)
Eumentis Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for serious neuropsychiatric conditions.
Biotech
ATAI Life Sciences AG is a biopharmaceutical company headquartered in Munich, Germany, focused on acquiring and developing innovative treatments for mental health disorders.
Similar biotechnology company
Lykos Therapeutics is a biotechnology company developing psychedelic-assisted therapies, particularly MDMA-assisted therapy for post-traumatic stress disorder (PTSD). It works with clinicians and researchers to advance regulated treatments for people with PTSD and related mental-health conditions.
Similar biotechnology company
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Similar biotechnology company
Reunion Neuroscience is a clinical-stage biopharmaceutical company that develops innovative therapeutics for underserved mental health disorders. Its lead drug candidate, luvesilocin, is a proprietary 5-HT2A agonist designed to provide durable antidepressant effects for patients with mood and anxiety disorders.
Similar biotechnology company
AtaiBeckley Inc. has its corporate headquarters located in New York, USA. The biopharmaceutical company is on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments.
Biotech
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Biotech
Synendos Therapeutics is a clinical-stage biopharmaceutical and neuroscience company focused on developing a novel class of small molecules to treat psychiatric and neurological disorders.
Biotech
Elkedonia is a biotechnology company committed to introducing a pioneering, first-in-class antidepressant treatment utilizing precision medicine. Headquartered in Strasbourg, France, the company brings together stakeholders across the European ecosystem to advance innovative therapeutics.
Similar biotechnology company
Gilgamesh Pharma Inc. is a clinical-stage neuroscience company that develops novel chemical entities to treat psychiatric diseases, aiming to move beyond symptom management toward rapid-acting and durable therapies. The company utilizes an AI-powered discovery platform and medicinal chemistry to create precision therapies targeting conditions such as depression, anxiety, addiction, and schizophrenia.
Biotech
Beckley Psytech is a UK-based clinical-stage biotechnology company developing psychedelic medicines for psychiatric and neurological disorders. Its programs have included BPL-003, an intranasal formulation of 5-MeO-DMT, intended for conditions such as treatment-resistant depression and alcohol use disorder.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Serenatis Bio and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Serenatis Bioand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →